Our company has built a platform to produce high-quality cells and tissues for regenerative medicine. That pursuit involves multiple disciplines, which means everyone here is an expert in a different language. Some of us are fluent in stem-cell biology, others in optical engineering, others in machine learning. When we started the company it wasnt possible to do biology and engineering under the same roof. When we finally moved into a shared space we were able to learn each others lexicons, and we became more strongly aligned. And now that were all working separately, the bonds created in that process have helped us deal with things. We cant discuss technical details at our desks anymore, but weve learned new ways of working together. Its important to stay in sync as a team, and in a covid-19 world thats never felt more true.
TIM O'CONNELL
Founded Blendoor, a job-search platform that hides candidates names and photos in the initial stages to reduce unconscious bias.
I started coding at 13, and that has gotten me pretty far in my career (Stanford, MIT, Microsoft). I once viewed humanities and social science education as nice-to-haves but not need-to-haves. It wasnt until I came face to face with the harsh realities of inequity and the paradox of meritocracy that I realized that artificial intelligence is far from solving many of our most challenging problems as a human race (for example, xenophobia, sexism, racism, homophobia, impostor syndrome, and unconscious bias).
The externalities that influence creativity, adoption, and scale are often more important than the innovation itself. To be a successful innovator one has to be really in tune with whats happening in the world on a global scale (or be really lucky, or better yet both). Venture capital has shortened the learning curve for some innovators, but bias has limited access to venture capital for many. Unconscious bias is like an odorless gasits imperceptible to most, but pervasive and deadly.
To optimize the innovation ecosystem, institutions must invest more in leveling the playing field. Today and for much of the documented past, innovation has been reserved for the children of middle- and upper-class parents. (Research the founders of companies valued at over $1 billion.) We laud the proverb Necessity is the mother of invention, but the people who grow up needing the most, independent of their intelligence, are often left out of the innovation game. As with all games, the best players emerge when the barriers to entry are low, the rules/standards are equally enforced, and there is high transparency across the board.
Audre Lorde once wrote: The masters tools will never dismantle the masters house.
I am a short, melanin-enriched, queer female on planet Earth. In some ways its easier to be innovative when youre invisible, but at some point, you need tools to scale: capital, team, mentorship. The one thing I know now that I wish I had known earlier is that my path toward getting the tools I need looks a lot different from the paths of others. Its not better nor worsesimply different. The hardest part is carving it out. Now that I know my path isnt blockedrather, it just didnt existIm way better equipped to win.
COURTESY PHOTO
Founded DotLab, which makes diagnostic tests focused on womens health.
About a decade ago I worked at the White House Office of Science and Technology Policy, whose goal was to speed up the commercialization of technologies being developed in federally funded labs. While there I saw that some of the most important work done by the government involved things the media paid no attention tofor example, the way it could use investments in research and development to fuel private--sector innovation.
In 2009, the Obama administration released the Strategy for American Innovation. The idea behind it was to establish the critical nature of federal government support for R&D. In particular it stressed the spillover effects, or the idea that investments in such research end up being beneficial to people unrelated to the original investment. Or to put it another way, R&D investment is a public good. Analyses at the time suggested that in order to produce economic growth we should be doubling or quadrupling our R&D investments. Instead that spending has since been slashed, especially in basic research.
President Obama also launched a Lab to Market Initiative meant to speed the path to market for technologies stemming from government--funded research. There were also pilot programs designed to increase the use of government-funded R&D facilities by entrepreneurs, create incentives to commercialization, and improve, among other things, the impact of the Small Business Innovation Research (SBIR) program.
My own company, DotLab, ended up being a beneficiary. We develop novel molecular diagnostic tests for prevalent yet underserved diseases affecting womens health. Its notoriously difficult for this field of early--stage diagnostics to attract private investment, because of unclear regulatory pathways, low reimbursement rates, or resistance to change among physiciansor all of the above. Many promising diagnostic technologies never make it to patients because its so hard for these types of companies to get financing. A grant from the SBIR was critical to our early success. I cant be sure that wed be here today without it.
COURTESY PHOTO
Founded Ubiquitous Energy, which makes transparent solar cells that can be put on windows or device screens.
I used to imagine innovators as individuals, as most people probably dothe genius inventor divining solutions in a lab or garage. But this picture that people have is not only wrong; it hinders our ability to innovate effectively.
Eight years ago I cofounded Ubiquitous Energy, a company based on an innovation Id helped to launch from an MIT laba transparent solar cell that promised new ways of deploying solar technology, like windows that generate energy or consumer devices powered by their own displays. I learned that in the messy, scrappy world of tech startups, the key to innovation is to make it a team sport.
Taking any innovation from the lab to commercial reality requires engaging with all sorts of people. You need to work with engineering, R&D, business development, and sales teams, as well as investors, advisors, and customers. By thoughtfully designing teams and carefully tending to the connections among them, you ensure that innovation doesnt happen in a vacuum. If you isolate the engineering team you risk creating an innovative technology that doesnt have a customer. If you listen only to the customer you might conceive of a product that cant practically be made. Neglect investors and you can find yourself with a business plan that nobody wants to fund.
Working among people with competing priorities takes more effort. It means encouraging communication so theyre aware of each others needs as they generate new ideas. You have to find a way to invite these ideas in, make it okay for people to disagree respectfully, and encourage the flow of ideas among the various groups. You need each person to focus on his or her task, but not so much that it creates boundaries and kills any sense of creativity in the group.
Ive found that viewing innovation as a team sport instills a creative culture that makes an organization better. The innovations that result are far greater than anything that might have come from any one person operating independently.
CHRIS SCIACCA / IBM RESEARCH
Founded Somalias first incubator and start-up accelerator; now at IBM Research.
People tend to think innovation can be neatly placed into two categories: incremental or disruptive. They also assume that the only category that really matters is the disruptive kind, where you dramatically transform markets or introduce a novel product. And yes, disruptive innovations in CRISPR, quantum computing, or batteries are undoubtedly worth the headlines.
But Ive learned that there is immense value in incremental innovation. When you improve an existing product to cut costs, or when you make that product more efficient or user friendly, thats what pays the bills. And in fact those little innovations can give you the needed tailwind to go after the disruptive ideas, which can take years to incubate and bring to fruition. Never underestimate the importance of incremental improvements.
TIM O'CONNELL
Cofounded Imprint Energy, which is developing thin, flexible, and safe print- able batteries.
As a CEO of a startup, you get used to hearing no. You also face an endless succession of what feel like earth--shattering crises, like nearly running out of cash, losing a key customer, discovering a widespread product failureor having to shut down operations because of a global pandemic. But it turns out that these disasters can actually be good for you. In fact, Im not sure you can innovate without them. Heres what all our crises have taught me.
Its good to be uncomfortable. We once had a key customer request a battery capability that wed never deployed before. The customer made it clear that if we couldnt develop this capability theyd be less confident in our product. We wrestled with the risks, not least of which was the potential embarrassment if we couldnt meet the customers needs. We knew wed face many technical problems with no obvious solutions if we tried to pull it off. Yet we decided to try to satisfy the customer, even if it wasnt obvious at first how we could get it done. A few weeks later we delivered something beyond what the customer had asked for, and weve since grown this capability into a powerful sales tool and potential revenue streamnot to mention it strengthened our relationship with the customer.
Short-term failure is good. A few years ago our company began to scale up our manufacturing output in response to a customers need. In the process we discovered aberrations we hadnt seen during smaller-scale production. Our team dived into failure analysis, and we finally attributed the problem to a single material within the battery. Wed used this material for years, but now we needed a replacement. Once we deployed that change, the battery quality, reliability, and manufacturability drastically improved.
Its okay to be vulnerable. One of my hardest days as Imprints CEO was the day I found out I was pregnant. We were in the middle of raising a funding round, we had begun scaling our manufacturing output, and I had been traveling nonstop for a year. Until that day, I had assumed that my role as CEO was to exude strength and confidence. With the mounting pressure I was harder on myself than I needed to be, and now I had the added stress of being pregnant. I decided to acknowledge to my team that I was overwhelmed. They rallied together and found ways to operate more efficiently and communicate more effectively, supporting me to focus my time and leverage on our most pressing goals. This gave me not only the space to plan for the companys future, but also the resiliency to prepare for my own new normal: leading while becoming a first-time mother.
Read the original:
Six tales from the trenches of running a startup - MIT Technology Review
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 003 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 004 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 005 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 006 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 007 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 008 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 009 Stem Cell Therapy: Age of Human Cell Engineering is Born [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 010 Using Stem Cells Scientists Grow a Rat Lung, Humans are Next [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 011 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 012 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 013 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 014 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 015 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 18th, 2011] [Originally Added On: January 18th, 2011]
- 016 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 7th, 2011] [Originally Added On: February 7th, 2011]
- 017 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 018 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 019 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 020 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 021 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 022 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 023 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 024 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 025 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 026 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 027 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 028 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 029 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 030 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 031 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 032 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 033 Dr Farshchian: Regenerative Medicine shows Potentials - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 034 Mayo Clinic Regenerative Medicine Consult Service - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- 035 Regenerative Medicine and Applications of Stem Cell Research - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 036 The Future of Stem Cells and Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 037 "You and Your Health" TV Show - Orthopedic Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 038 Closing Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 039 Hearing Loss Research: CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 040 An amazing story of stem cells, regenerative medicine and healing power: - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 041 What is Regenerative Medicine? | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 042 A New Era in Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 043 McEwen Centre for Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 044 Retroviruses, Reproduction, and Regenerative Medicine: The Influence of Federal Funding - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 045 You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 046 TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 047 Regenerative Medicine: Pathways to Cure - Version 2.0 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 048 Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- 049 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 050 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 051 Coast To Coast AM - 15.11.2011 - 4/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 052 Coast To Coast AM - 15.11.2011 - 1/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 053 Stem Cell Based Therapies for Blindness: David Hinton - CIRM Science Writer's Seminar - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- 054 Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 055 Coast To Coast AM: Regenerative Medicine / Dulce Base 11-15-2011 Download Link - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 056 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 057 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 058 StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- 059 StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 060 StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 061 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 062 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 063 2011 Summit: Harnessing Regenerative Medicine for US Service-members, Major General James K. Gilman - Video [Last Updated On: December 17th, 2011] [Originally Added On: December 17th, 2011]
- 064 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 065 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 066 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 067 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 068 Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- 069 Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 23rd, 2011] [Originally Added On: December 23rd, 2011]
- 070 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 071 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 072 Regenerative medicine company encouraged by heart failure trial [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- 073 IndiaMART Leaders of Tomorrow AWards 2011 - Regenerative Medical Services Pvt Ltd - Video [Last Updated On: February 8th, 2012] [Originally Added On: February 8th, 2012]
- 074 American CryoStem Joins Alliance for Regenerative Medicine [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- 075 ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 076 Biomask: Improving Facial Burn Treatment for Soldiers in the Field [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 077 Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 078 Histogenics to Present at 7th Annual New York Stem Cell Summit [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 079 BioTime CEO Michael D. West to Present at New York Stem Cell Summit [Last Updated On: February 18th, 2012] [Originally Added On: February 18th, 2012]
- 080 Makucell(TM) Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate(TM) [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]